Discussion on structure classification and regulation function of histone deacetylase and their inhibitor
Chemical Biology & Drug Design · 2024-01 · 103 (1)
DOI: 10.1111/cbdd.14366 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Chemical Biology & Drug Design, online erschienen am 30.09.2023. Verfasst von Han Han und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, Shenyang Medical College, Shenyang City, P. R. China. Hauptthemen laut MEDLINE: Histone Deacetylase Inhibitors, Neoplasms. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 138 Literaturangaben. Gefördert von: Natural Science combination Foundation for improving innovation of Liaoning Province (2022-NLTS-14-01).
Abstract (Originalsprache)
Epigenetic regulation of genes through posttranslational regulation of proteins is a well‐explored approach for disease treatment, particularly in cancer chemotherapy. Histone deacetylases have shown significant potential as effective drug targets in therapeutic studies aiming to restore epigenetic normality in oncology. Besides their role in modifying histones, histone deacetylases can also catalyze the deacetylation of various nonhistone proteins and participate in the regulation of multiple biological processes. This paper provides a review of the classification, structure, and functional characteristics of the four classes of human histone deacetylases. The increasing abundance of structural information on HDACs has led to the gradual elucidation of structural differences among subgroups and subtypes. This has provided a reasonable explanation for the selectivity of certain HDAC inhibitors. Currently, the US FDA has approved a total of six HDAC inhibitors for marketing, primarily for the treatment of various hematological tumors and a few solid tumors. These inhibitors all have a common pharmacodynamic moiety consisting of three parts: CAP, ZBG, and Linker. In this paper, the structure–effect relationship of HDAC inhibitors is explored by classifying the six HDAC inhibitors into three main groups: isohydroxamic acids, benzamides, and cyclic peptides, based on the type of inhibitor ZBG. However, there are still many questions that need to be answered in this field. In this paper, the structure‐functional characteristics of HDACs and the structural information of the pharmacophore model and enzyme active region of HDAC is are considered, which can help to understand the inhibition mechanism of the compounds as well as the rational design of HDACs. This paper integrates the structural‐functional characteristics of HDACs as well as the pharmacophore model of HDAC is and the structural information of the enzymatic active region, which not only contributes to the understanding of the inhibition mechanism of the compounds, but also provides a basis for the rational design of HDAC inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Biology, Shenyang Medical College, Shenyang City, P. R. China.
- Department of Pathogen Biology, Shenyang Medical College, Shenyang City, P. R. China.
Förderung
- Natural Science combination Foundation for improving innovation of Liaoning Province (2022-NLTS-14-01)
Zitieren
APA
Han, H., Feng, X., He, T., Wu, Y., He, T., Yue, Z., & Zhou, W. (2024). Discussion on structure classification and regulation function of histone deacetylase and their inhibitor. Chemical Biology & Drug Design, 103(1). https://doi.org/10.1111/cbdd.14366
Vancouver
Han H, Feng X, He T, Wu Y, He T, Yue Z, et al. Discussion on structure classification and regulation function of histone deacetylase and their inhibitor. Chemical Biology & Drug Design. 2024;103(1). doi:10.1111/cbdd.14366
BibTeX
@article{Han2024,
author = {Han, Han and Feng, Xue and He, Ting and Wu, Yingfan and He, Tianmei and Yue, Ziwen and Zhou, Weiqiang},
title = {Discussion on structure classification and regulation function of histone deacetylase and their inhibitor},
journal = {Chemical Biology & Drug Design},
year = {2024},
volume = {103},
number = {1},
doi = {10.1111/cbdd.14366}
}
EUVIMED